What is the recommended regimen for initiating and managing LHRH (GnRH) therapy as primary hormonal treatment in a man with prostate cancer requiring androgen suppression?

LHRH Therapy for Prostate Cancer: Recommended Regimen

First-line hormonal management of prostate cancer requiring androgen suppression should be based on LHRH agonist or bilateral orchiectomy as monotherapy, without routine addition of antiandrogens for combined androgen blockade. 1, 2

Initial Treatment Selection

Primary Options (Equally Effective)

• LHRH agonist (medical castration) - Most commonly chosen by patients
• Bilateral orchiectomy (surgical castration) - Equally effective, lower cost, eliminates compliance issues 2

LHRH agonists and orchiectomy are equally effective at achieving castration (testosterone <50 ng/mL). 2 Most patients prefer medical castration over the permanent psychological impact of surgery.

LHRH Agonist vs Antagonist Choice

For patients with overt metastases or high tumor burden at risk of disease flare, strongly consider LHRH antagonist (degarelix or relugolix) as first-line therapy. 3, 4, 5

Key differences:

• LHRH agonists cause initial testosterone surge requiring antiandrogen co-administration for ≥7 days in patients with metastases 2
• LHRH antagonists provide immediate testosterone suppression without surge, eliminating flare risk and antiandrogen need 1, 3, 4

Critical Management Protocol for LHRH Agonists

Preventing Testosterone Flare (LHRH Agonists Only)

Antiandrogen therapy must precede or be co-administered with LHRH agonist initiation and continued for at least 7 days in patients with overt metastases. 2 This prevents disease flare from the initial testosterone surge.

Common pitfall: Failing to use antiandrogen coverage in metastatic patients can precipitate clinical flare with worsening bone pain, spinal cord compression, or urinary obstruction. 5

When LHRH Antagonists Are Preferred

Use LHRH antagonist (not agonist) in these high-risk scenarios: 4, 5

• Impending spinal cord compression
• Severe bone pain from metastases
• High tumor burden requiring rapid symptom control
• Urinary obstruction from prostate cancer
• Patient refusal/contraindication to antiandrogens

The antagonist achieves castrate testosterone levels within 3 days without surge, providing faster symptom relief. 4, 6

Combined Androgen Blockade: NOT Recommended

Do not routinely add antiandrogens to LHRH agonist/orchiectomy for combined androgen blockade in metastatic disease. 1, 2, 1

The evidence is clear: Meta-analysis of 27 trials showed 5-year survival of 25.4% with combined blockade vs 23.6% with castration alone (P=0.11). 1 While non-steroidal antiandrogens showed minimal survival benefit (27.6% vs 24.7%, P=0.005), recent large trials found no benefit but worse quality of life. 1, 3

The minimal potential survival benefit does not justify the added cost, toxicity, and reduced quality of life. 1

Continuous vs Intermittent ADT

Use continuous ADT for metastatic disease. 1

A large phase III trial (>3000 patients, 9.8 years follow-up) showed median survival of 5.8 years with continuous ADT vs 5.1 years with intermittent (HR 1.1,90% CI: 0.99-1.23), failing to establish non-inferiority of intermittent therapy. 1

Intermittent ADT may be considered for biochemical relapse without metastases for quality-of-life benefits, as it appears non-inferior in this specific population. 1

Monitoring Requirements

Target testosterone suppression: <50 ng/mL 2

Monitor for ADT adverse effects: 2

• Osteoporosis screening and treatment per guidelines
• Cardiovascular risk assessment
• Metabolic syndrome (diabetes, lipids, obesity)
• Fracture risk evaluation

Note on cardiovascular risk: Recent real-world data suggests potential differences in cardiovascular events between agonists and antagonists, though this remains controversial and requires further validation. 7, 8

Timing of ADT Initiation

Immediate ADT is indicated (Category 1) for: 2

• Tumor-related symptoms
• Overt metastases
• Positive lymph nodes after radical prostatectomy

For biochemical recurrence alone, ADT timing should be individualized based on: 2, 1

• PSA doubling time (<3 months warrants earlier treatment)
• Absolute PSA level (>50 ng/mL suggests earlier treatment)
• Life expectancy
• Patient symptoms/anxiety

Avoid routine ADT for asymptomatic biochemical recurrence unless PSA doubling time <3 months, symptomatic progression, or proven metastases. 1, 3, 1

Practical Algorithm

1. Assess disease burden and urgency

   • High tumor burden/impending complications → LHRH antagonist
   • Standard metastatic disease → LHRH agonist OR antagonist

2. If choosing LHRH agonist for metastatic disease:

   • Start antiandrogen 7 days before or simultaneously
   • Continue antiandrogen ≥7 days
   • Verify castrate testosterone achieved

3. If choosing LHRH antagonist:

   • No antiandrogen needed
   • Faster symptom relief expected

4. Do NOT add antiandrogen for combined blockade beyond initial flare prevention

5. Continue ADT continuously for metastatic disease

6. Monitor testosterone levels and ADT-related complications